Enhanced MHC-I-mediated antigen presentation underlies improved CD8+T activation in BCR-ABL1+ B-ALL treated with CD19@NP/17-DMAG and Imatinib. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.